Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748380 | 0.84 | HSD17B10 (0.31) | — | |
| SCHEMBL17748392 | 0.79 | HTT (0.37) | — | |
| SCHEMBL17748388 | 0.79 | HSD17B10 (0.35) | — | |
| SCHEMBL10225885 | 0.78 | PDE2A (0.39) | ESR1ESR2 | |
| SCHEMBL17748387 | 0.72 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL1922844 | 0.72 | ESR2 (0.42) | ESR1ESR2 | |
| SCHEMBL2561411 | 0.71 | SRC (0.42) | SRC | |
| SCHEMBL31176234 | 0.71 | SRC (0.42) | SRC | |
| SCHEMBL22753817 | 0.70 | SKP2 (0.55) | ESR1ESR2 | |
| SCHEMBL17748386 | 0.70 | RXRA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074714-B | Improvements in or relating to organic compounds | 奇华顿股份有限公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-3218342-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-10138195-B2 | Organic compounds | Givaudan, S.A. (CH) | 2018-11-27 | — | — | US | disclosed |
| US-20170297993-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2017-10-19 | — | — | US | disclosed |
| EP-3218342-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016074698-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138195-B2 | Organic compounds | CHRM4, CHRM5, CHRM1 | SRC 4198/4885ESR1 2706/4885ESR2 3928/4885 |
| US-20170297993-A1 | ORGANIC COMPOUNDS | CHRM4, CHRM5, CHRM1 | SRC 4198/4885ESR1 2706/4885ESR2 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.